Centauri Therapeutics publishes proof-of-concept data demonstrating activity of a novel bifunctional immunotherapy against Gram-negative bacterial infections

June 10, 2025 | News

Paper presents the first pre-clinical application of endogenous antibody recruitment to address multi-drug resistant Gram-negative infections
Novel bifunctional molecule based on Alphamer^® platform demonstrated direct, broad-spectrum antibacterial activity in vitro and in vivo, with enhanced immune activation through anti-αGal antibody recruitment